其他
重磅发布:益生菌产业发展十大趋势
趋势一
终端产品竞争激烈,赢家暂不明
趋势二
中国原料企业崛起
趋势三
积极循证和打造菌株品牌成为主流
趋势四
更高标准和更权威指南逐步推出
趋势五
益生菌的营养属性被更多提及和认可
趋势六
活菌药物行将突破
趋势七
二代益生菌的研究和产业化取得进展
趋势八
肠外益生菌兴起
趋势九
非细菌非活菌产品被更广泛关注和应用
趋势十
大数据和人工智能助力产业创新
1.周光宏,在第十五届益生菌与健康国际研讨会上的发言。2020年8月19-21日,南京,http://www.cifst.org.cn/a/dynamic/dongtai/20200820/1931.html2.热心肠小伙伴们,深度解析:上市2天暴涨58.4%,科拓生物的创新有多强。《肠道产业》微信公众号,https://mp.weixin.qq.com/s/5gHgDvnvR0Uyd__DDeqSaw3.Hill C, Guarner F, Reid G, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J]. Nature reviews Gastroenterology & hepatology, 2014, 11(8): 506.4.Gibson G R, Hutkins R, Sanders M E, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nature reviews Gastroenterology & hepatology, 2017, 14(8): 491.5.Swanson K S, Gibson G R, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics[J]. Nature Reviews Gastroenterology & Hepatology, 2020: 1-15.6.国卫办食品函〔2018〕795号,关于公开征求2018年度食品安全国家标准立项计划(征求意见稿)意见的函,2018年9月12日,http://www.nhc.gov.cn/sps/s3593/201809/c9f6a33d05574ae3bf64fcd9e9cf1d05.shtml7.国家市场监督管理总局,《益生菌类保健食品申报与审评规定(征求意见稿)》公开征求意见的反馈,2019年5月15日,http://www.samr.gov.cn/hd/zjjg/201907/t20190715_303461.html8.World Gastroenterology Organisation, WGO Practice Guideline - Probiotics and Prebiotics, https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics9.陈洁,程茜,黄瑛,黄永坤,黄志华,楼金玕,舒赛男,王宝西,王文建,武庆斌,张琳,郑跃杰.益生菌儿科临床应用循证指南[J].中国实用儿科杂志,2017,32(02):81-90.10.van den Akker C H P, van Goudoever J B, Shamir R, et al. Probiotics and Preterm Infants: A Position Paper by the European Society for Paediatric Gastroenterology Hepatology and Nutrition Committee on Nutrition and the European Society for Paediatric Gastroenterology Hepatology and Nutrition Working Group for Probiotics and Prebiotics[J]. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70(5): 664-680.11.Su G L, Ko C W, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders[J]. Gastroenterology, 2020, 159(2): 697-705.12.Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results | Seres Therapeutics, https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-announces-us-food-and-drug-administration13.Recurrent C. diff Infection | Positive Preliminary Pivotal Phase 3 Data for RBX2660 | Rebiotix Inc. https://www.rebiotix.com/news-media/press-releases/rebiotix-announces-worlds-first-positive-pivotal-phase-3-data-investigational-microbiome-based-therapy-rbx2660/14.4D pharma announces comprehensive clinical benefit data from Part A of combination trial of MRx0518 and Keytruda®. https://www.4dpharmaplc.com/en/newsroom/press-releases/comprehensive-clinical-benefit-data-part-a-mrx0518-and-keytruda15.Pendulum Therapeutics Announces Publication Of Clinical Data For First-Ever Medical Probiotic That Provides The Dietary Management Of Healthy A1C And Blood Glucose Levels BioSpace. https://www.biospace.com/article/releases/pendulum-therapeutics-announces-publication-of-clinical-data-for-first-ever-medical-probiotic-that-provides-the-dietary-management-of-healthy-a1c-and-blood-glucose-levels/16.Scheiman J, Luber J M, Chavkin T A, et al. Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism[J]. Nature medicine, 2019, 25(7): 1104-1109.17.Wang K, Liao M, Zhou N, et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids[J]. Cell reports, 2019, 26(1): 222-235. e5.18.Wang K, Liao M, Zhou N, et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids[J]. Cell reports, 2019, 26(1): 222-235. e19.AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure AOBiome. https://www.aobiome.com/pressreleases/aobiome-completes-patient-enrollment-in-phase-2-clinical-trial-of-lead-candidate-b244-to-treat-elevated-blood-pressure/20.De Boeck I, van den Broek M F L, Allonsius C N, et al. Lactobacilli have a niche in the human nose[J]. Cell Reports, 2020, 31(8): 107674.21. Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study[J]. Nature medicine, 2019, 25(7): 1096-1103.22.Wang S, Ahmadi S, Nagpal R, et al. Lipoteichoic acid from the cell wall of a heat killed Lactobacillus paracasei D3-5 ameliorates aging-related leaky gut, inflammation and improves physical and cognitive functions: from C. elegans to mice[J]. Geroscience, 2020, 42(1): 333-352.23.Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial[J]. The Lancet Gastroenterology & Hepatology, 2020.24.Sutcliffe S B, Kalyan S, Pankovich J, et al. Novel microbial-based immunotherapy approach for Crohn’s disease[J]. Frontiers in medicine, 2019, 6: 170.25.The Best Custom Probiotics For Improving Your Gut Health Sun Genomics. https://sungenomics.com/.